OCUL
Ocular Therapeutix, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2014-07-25
$6.82
+0.09 (+1.34%)
last quote
Want the full multi-source brief on OCUL?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$6.82
High
$6.97
Low
$6.76
Previous close
$6.73
Fundamentals
Market cap
$1.48B
P/E (TTM)
—
P/S (TTM)
28.39x
P/B
3.95x
Gross margin
87.11%
Operating margin
-603.04%
Net margin
-579.10%
Rev growth (YoY)
-8.14%
EPS growth (YoY)
—
ROE
-59.87%
52W high
$16.44
52W low
$6.00
Beta
1.24x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-09in 4 daysbefore market
Q3 2026EPS est $-0.37Rev est $14.4M
Recent SEC filings
CIK 1393434filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 15h
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Corcept (CORT) delivered earnings and revenue surprises of +48.53% and +3.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · 2d
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 20
Yahoo · 6d
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026. Upcoming Investor Conference: UBS Global Biopharma Conference 2026: Date: Tuesday, November 17, 2026Fireside
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial